Ken Griffin Bolt Biotherapeutics, Inc. Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.73 - $1.5 $35,198 - $72,325	-48,217 Reduced 2.0%	2,367,511 $1.78 Million
Q1 2024 May 15, 2024	SELL	$1.01 - $1.4 $43,662 - $60,521	-43,230 Reduced 1.76%	2,415,728 $3.38 Million
Q4 2023 Feb 14, 2024	SELL	$0.85 - $1.12 $335,474 - $442,037	-394,676 Reduced 13.83%	2,458,958 $2.75 Million
Q3 2023 Nov 14, 2023	SELL	$0.98 - $1.46 $129,862 - $193,468	-132,513 Reduced 4.44%	2,853,634 $2.97 Million
Q2 2023 Aug 14, 2023	BUY	$1.27 - $1.95 $187,581 - $288,018	147,702 Added 5.2%	2,986,147 $3.82 Million
Q1 2023 May 15, 2023	BUY	$1.29 - $1.66 $111,305 - $143,229	86,283 Added 3.14%	2,838,445 $3.95 Million
Q4 2022 Feb 14, 2023	BUY	$1.26 - $1.51 $143 - $172	114 Added 0.0%	2,752,162 $3.58 Million
Q3 2022 Nov 14, 2022	SELL	$1.48 - $2.61 $4,851 - $8,555	-3,278 Reduced 0.12%	2,752,048 $4.07 Million

19.1M

Ticker BOLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,641,500
Market Cap $21.5M
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.